# 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

> **NCT00005982** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome

## Interventions

- **DRUG:** nelarabine
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00005982
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-04
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005982, "506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00005982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*